Robert Axtell
Assistant professor
Medicine
Oklahoma Medical Research Foundation
United States of America
Biography
B.S., Idaho State University, Pocatello, ID, 1999 M.S., Idaho State University, Pocatello, ID, 2001 Ph.D., University of Alabama at Birmingham, 2007 Postdoc, Stanford University, 2007-2013
Research Interest
Immunological heterogeneity impacts treatment response to IFN-β in patients with MS; Regulatory B-cells play a key role in the efficacy of IFN-β in both patients with MS and mice with EAE; The T Helper (TH) 17 pathway dictates non-response to IFN-β therapy in mice with EAE
Publications
-
Larabee CM, Hu Y, Desai S, Georgescu C, Wren JD, Axtell RC, Plafker SM. Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice. Mol Vis. 2016 Apr 11;22:332-41. [Abstract]
-
Larabee CM, Desai S, Agasing A, Georgescu C, Wren JD, Axtell RC, Plafker SM. Loss of Nrf2 exacerbates the visual deficits and optic neuritis elicited by experimental autoimmune encephalomyelitis. Mol Vis. 2016 Dec 30;22:1503-1513. [Abstract]
-
Berkovich R, Bakshi R, Amezcua L, Axtell RC, Cen SY, Tauhid S, Neema M, Steinman L. Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. Ther Adv Neurol Disord. 2017 Jan;10(1):3-17. [Abstract]
